Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7333-7338

  Shao, Li En ^a   Tanaka, Tetsuya ^a   Gribi, Ruby ^a   Yu, John ^a   Diccianni, Mitchell B ^b   Yu, Alice L ^b   Pullen, Jeanette D ^c   Camitta, Bruce M ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d Midwest children'S' Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPROPYL 2 IMIDAZOLYLDISULFIDE; ANTINEOPLASTIC AGENT; IV 2; RECOMBINANT PROTEIN; RECOMBINANT THIOREDOXIN; THIOREDOXIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS; CHILD; DISULFIDES; HEMATOPOIETIC STEM CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, T-CELL, ACUTE; LEUKOCYTE COUNT; THIOREDOXIN; TUMOR STEM CELLS;

EID: 0035476202     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Thioredoxin and glutaredoxin systems
2. Enzymatic synthesis of deoxyribonucleotides. VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B
3. Oxidation-reduction and the molecular mechanism of a regulatory RNA-protein interaction
4. Thioredoxin regulates the DNA binding activity of NF-KB by reduction of a disulphide bond involving cysteine 62
5. Human transcription factor IIIC (TFIIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding
6. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes
7. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin
8. Redox regulation of fos and jun DNA-binding activity in vitro
9. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1
10. ADF, a growth-promoting factor derived from adult T cell leukemia and homologous to thioredoxin: Involvement in lymphocyte immortalization by HTLV-1 and EBV
11. Expression and growth-promoting effect of T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma
12. Coexpression of adult T-cell leukemia-derived factor. A human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium
13. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide
14. Redox control of resistance to cis-diamminedichloroplatium (II) (CDDP): Protective effect of human thioredoxin against CDDP-induced cytotoxicity
15. A method for cloning T lymphocytic precursors in agar
16. Characterization of the potentiation effect of activin on human erythroid colony formation in vitro
17. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia
18. Adult T-cell leukemia-derived factor/thioredoxin produced by both human T-lymphotropic virus type 1 and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2
19. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin
20. Acute lymphoblastic leukemia and non-Hodgkin's lymphoma of T lineage: Colony-forming cells retain growth factor (interleukin 2) dependence
21. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression
22. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues
23. Thioredoxin redox signaling: A novel target for anti-cancer drug development
24. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
25. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction
26. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin
27. Cloning and expression of a cDNA for human thioredoxin
28. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors
29. Thioredoxin and thioredoxin reductase
30. Thioredoxin/adult T-cell leukemia-derived factor (ADF), and redox regulation
31. Identification of redox/repair protein Ref-1 as a potent activator of p53
32. Thioredoxin-dependent redox regulation of p53-mediated p21 activation
33. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
34. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo
35. Transfection with human thioredoxin increases cell proliferation and a dominant negative mutant thioredoxin reverses the transformed phenotype of breast cancer cells
36. 1
37. Redox control of caspase-e activity by thioredoxin and other reduced proteins
38. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study
39. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway
40. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells
41. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism
42. Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor
43. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia
44. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging